Crinetics Buy Rating: Derisked Atumelnant CAH Program and Outperforming Palsonify Launch Signal Undervalued Shares

Crinetics Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on the stock and has a $99.00 price target.

Cory Jubinville, PhD has given his Buy rating due to a combination of factors tied to both Crinetics’ clinical and commercial execution. He views the new Phase 2 Cohort 4 and open-label extension data for atumelnant in congenital adrenal hyperplasia as strongly supportive of the drug’s potential, particularly because substantial reductions in androstenedione were achieved without sacrificing the ability to lower glucocorticoid doses toward physiological levels. This contrasts with emerging standard-of-care data suggesting many patients currently face a trade-off between controlling androgen levels and reducing steroid burden, positioning atumelnant as a potentially differentiated therapy. The absence of liver safety issues at clinically relevant doses further reinforces confidence in the ongoing Phase 3 Calm-CAH trial and increases the perceived probability of success for the program.

In addition, Jubinville highlights that the early commercial rollout of Palsonify for acromegaly has exceeded internal expectations, with first full-quarter revenues and patient enrollment metrics meaningfully ahead of his prior assumptions. The breadth of prescriber adoption and early formulary access indicate strong initial market receptivity and support a robust revenue ramp. These clinical and commercial positive surprises prompted him to raise his price target, reflecting higher projected cash flows and reduced risk across the pipeline. Taken together, the derisked CAH program, solid safety profile, and better-than-expected Palsonify launch underpin his conviction that Crinetics’ shares remain undervalued at current levels, justifying a Buy recommendation.

Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Tenaya Therapeutics, Tectonic Therapeutic, and Crinetics Pharmaceuticals. According to TipRanks, Jubinville, PhD has an average return of 15.1% and a 55.00% success rate on recommended stocks.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $81.00 price target.